Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
102.52
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect
February 18, 2025
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for.
Via
StockStory
Incyte to Present at Upcoming Investor Conferences
February 18, 2025
From
Incyte
Via
Business Wire
What's going on in today's pre-market session: S&P500 movers
↗
February 11, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Via
Chartmill
What Analysts Are Saying About Incyte Stock
↗
February 11, 2025
Via
Benzinga
Why Incyte (INCY) Shares Are Plunging Today
February 10, 2025
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 8.9% in the morning session after the company reported fourth-quarter results with full-year guidance for key products such as...
Via
StockStory
Insights into Incyte Q4 Earnings
↗
February 10, 2025
Via
Benzinga
NASDAQ:INCY, an undervalued stock with good fundamentals.
↗
December 26, 2024
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday?
↗
February 10, 2025
Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while...
Via
Benzinga
Topics
Government
World Trade
Uncover the latest developments among S&P500 stocks in today's session.
↗
February 10, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via
Chartmill
Gapping S&P500 stocks in Monday's session
↗
February 10, 2025
Let's have a look at the S&P500 gap up and gap down stocks in today's session.
Via
Chartmill
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
↗
December 19, 2024
Via
Benzinga
Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches
↗
February 10, 2025
Incyte projects 2025 Jakafi revenue of $2.925B-$2.975B, up 4.76%-6.55%, and Opzelura sales of $630M-$670M, reflecting up to 31.81% growth.
Via
Benzinga
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4
February 10, 2025
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2024, with sales up 16.3% year on year to $1.18 billion. Its non-GAAP profit of $1.43 per share...
Via
StockStory
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
February 10, 2025
From
Incyte
Via
Business Wire
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
February 09, 2025
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect.
Via
StockStory
Earnings Scheduled For February 10, 2025
↗
February 10, 2025
Via
Benzinga
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Incyte
Via
Business Wire
Promising Signs: INCYTE CORP Setting the Stage for a Breakout.
↗
February 05, 2025
Exploring INCYTE CORP's Technical Signals and Breakout Potential: Based on good technical signals, INCYTE CORP is potentially setting up for a breakout.
Via
Chartmill
Investors should take notice of NASDAQ:INCY—it offers a great deal for the fundamentals it presents.
↗
January 24, 2025
Consider INCYTE CORP as a top value stock. NASDAQ:INCY shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced.
Via
Chartmill
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
January 21, 2025
From
Incyte
Via
Business Wire
Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline
↗
January 14, 2025
Incyte plans a transformational 2025 with four potential drug launches, pivotal trial readouts, and significant pipeline milestones targeting billion-dollar markets.
Via
Benzinga
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2025
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
December 17, 2024
From
Incyte
Via
Business Wire
Incyte Corporation (INCY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
December 17, 2024
Via
ACCESSWIRE
Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY
December 16, 2024
Via
ACCESSWIRE
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY
December 13, 2024
Via
ACCESSWIRE
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
↗
December 13, 2024
Via
The Motley Fool
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
December 10, 2024
From
Incyte
Via
Business Wire
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
December 07, 2024
From
Incyte
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
